Cellular therapies using regulatory T (Treg) cells are currently undergoing clinical trials for
the treatment of autoimmune diseases, transplant rejection and graft-versus-host disease. In …

Effective medical management for sickle cell disease (SCD) remains elusive. As a prevalent
and severe monogenic disorder, SCD has been long considered a logical candidate for …

Hematopoietic stem cells (HSCs) are the rare cells responsible for the lifelong curative
effects of hematopoietic cell (HC) transplantation. The demand for clinical-grade HSCs has …

Hematopoietic stem cells (HSCs) in adults are believed to be born from hemogenic
endothelial cells (HECs) in mid-gestational embryos. Due to the rare and transient nature …

Clinical transplants of hematopoietic stem cells (HSC) can provide a lifesaving therapy for
many hematological diseases; however, therapeutic applications are hampered by donor …

Myeloid malignancy is increasingly viewed as a disease spectrum, comprising
hematopoietic disorders that extend across a phenotypic continuum ranging from clonal …

Human pluripotent stem cells (hPSCs) provide an unparalleled opportunity to establish in
vitro differentiation models that will transform our approach to the study of human …

Diamond-Blackfan anemia (DBA) is a congenital disorder characterized by the failure of
erythroid progenitor differentiation, severely curtailing red blood cell production. Because …

Cell therapies and regenerative medicine interventions require an adequate source of
therapeutic cells. Here, we demonstrate that constructing in vivo osteo-organoids by …

Hematopoietic stem and progenitor cells (HSPCs) develop in distinct waves at various
anatomical sites during embryonic development. The in vitro differentiation of human …